Tirzepatide for PCOS: Evidence, Approval, and Pregnancy Risks

No. Tirzepatide is not approved for PCOS in the United States. Mounjaro is labeled for glycemic control in adults and pediatric patients 10 and older with type 2 diabetes, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk ^[13]. Zepbound is labeled to reduce excess body weight in adults with obesity, or overweight plus at least one weight-related comorbidity, and to treat moderate-to-severe obstructive sleep apnea in adults with obesity ^[12]. PCOS is not among the listed indications on either label, so prescribing it for PCOS is off-label unless a woman separately meets the weight or diabetes criteria [12, 13]. Both brands contain the same active ingredient, tirzepatide, a dual GIP and GLP-1 receptor agonist [12, 13].

The human evidence in PCOS comes from a single randomized trial: 60 overweight or obese Chinese women, treated for 16 weeks, with tirzepatide added to metformin in one arm and metformin alone in the other. The add-on group lost 10.4 kg versus 1.7 kg, recovered menstrual cycles at 53.6% versus 21.4%, and — after the drug was stopped — achieved pregnancy at 57.1% versus 25.0% by week 48 [1, 2]. The trial was small, single-center, open-label, and lasted only 16 weeks ^[2]. A larger placebo-controlled trial, PERIODS, is recruiting 198 women in Germany, with estimated primary completion in December 2028 ^[5]. Both US labels warn that tirzepatide may reduce the effectiveness of oral contraceptives [12, 13]. The Zepbound label advises discontinuing when pregnancy is recognized ^[12]; the Mounjaro label says use in pregnancy only if the potential benefit justifies the potential fetal risk ^[13].

Is Mounjaro or Zepbound FDA-approved for PCOS?

Neither brand carries a PCOS indication. Mounjaro’s listed indications are glycemic control in type 2 diabetes (adults and pediatric patients 10 and older) and reducing major adverse cardiovascular events in adults with type 2 diabetes at high cardiovascular risk; the label was revised in August 2026 ^[13]. Zepbound’s listed indications are chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity, and moderate-to-severe obstructive sleep apnea in adults with obesity; that label was also revised in August 2026 ^[12].

PCOS is not among the listed indications on either label [12, 13]. A woman with PCOS could still receive a prescription if she independently meets a labeled criterion — for example, obesity for Zepbound, or type 2 diabetes for Mounjaro. The PERIODS trial registry makes the gap explicit: tirzepatide is already approved for diabetes and obesity, but its effects on ovarian dysfunction in PCOS are not yet known ^[5].

What has actually been tested in women with PCOS?

The randomized evidence in PCOS consists of a single trial. Yang and colleagues published it in Diabetes, Obesity and Metabolism, first published online on 3 June 2026, registered as ChiCTR2400090908 [1, 2]. The authors themselves note that direct clinical research on tirzepatide in overweight or obese women with PCOS remains limited ^[2]. The study enrolled 60 overweight or obese Chinese women with PCOS at a single center, the Second Affiliated Hospital of Chongqing Medical University, in a prospective, open-label design with 1:1 randomization [1, 2].

Eligibility required the Rotterdam criteria for PCOS, a BMI of at least 24 kg/m2 (the Chinese cutoff for overweight), and age 18 to 40 ^[2]. The metformin-only arm (MET) titrated metformin up to 1000 mg twice daily. The combination arm (COM) took the same metformin regimen plus tirzepatide, started at 2.5 mg once weekly for the first 4 weeks and then increased to 5 mg weekly — a trial protocol, not a dosing recommendation [1, 2]. Treatment lasted 16 weeks. The primary outcome was change in body weight; secondary outcomes included body composition, reproductive hormones, metabolic markers, inflammation, and menstrual regularity [1, 2].

One point matters for reading every result below: this was not tirzepatide versus metformin. Both arms took metformin. The comparison tests only whether adding tirzepatide to metformin does more than metformin alone [1, 2]. The authors list their own limitations: a single center, a small sample, a short duration, Asian women only, and an open-label design ^[2].

How much weight did women lose on tirzepatide plus metformin?

At 16 weeks, the combination arm lost an average of 10.4 kg (SD 3.5) versus 1.7 kg (SD 2.5) with metformin alone, a difference with p < 0.001 [1, 2]. Body composition changes tracked the weight loss ^[2].

Measure at 16 weeks	Metformin + tirzepatide	Metformin alone
Body weight	−10.4 ± 3.5 kg	−1.7 ± 2.5 kg
BMI	−4.12 kg/m2	−0.68 kg/m2
Visceral adipose tissue	−34.13 cm2	−4.67 cm2
Total fat mass	about −7,494 g	about −516 g
Total lean mass	−2,743 g	−1,178 g

Weight and BMI differences had p < 0.001; the lean-mass difference had p = 0.033 [1, 2]. The combination arm also showed greater reductions in waist circumference, blood pressure, triglycerides, total and LDL cholesterol, and high-sensitivity CRP than the metformin-only arm ^[2].

Does tirzepatide help PCOS periods come back?

In this one trial, yes — more women resumed regular cycles when tirzepatide was added. All participants had menstrual irregularity at baseline, and the menstrual analysis covered 28 women per arm ^[2]. At 16 weeks, cycle recovery occurred in 53.6% (15 of 28) of the combination arm versus 21.4% (6 of 28) of the metformin-only arm, p = 0.013 ^[2]. Among the women who achieved cycle recovery, mean weight loss was 7.89 kg ^[2].

That last number is the key to interpretation. The hormone and cycle findings are consistent with an effect that runs through weight loss and metabolic improvement, and the trial provides no evidence of a weight-independent effect on the ovary [2, 11].

What happened to testosterone and other PCOS hormones?

DHEA-S and total testosterone fell more in the combination arm than with metformin alone (p = 0.016 and p = 0.010) ^[2]. Anti-Müllerian hormone (AMH) dropped by 3.64 ng/mL in the combination arm versus 1.00 ng/mL with metformin alone, p = 0.002 ^[2].

Not everything moved. There was no significant between-group difference in SHBG, estradiol, prolactin, LH, the LH/FSH ratio, or the free androgen index — which the trial defined as testosterone divided by SHBG, multiplied by 100 ^[2]. So the trial shows changes in some androgen markers and AMH, not a uniform correction of the PCOS hormone profile.

Did more women get pregnant?

The pregnancy numbers are the most quoted part of the trial, and they come with an important caveat: every pregnancy occurred after tirzepatide had been stopped. After week 16, both arms continued on metformin alone. Participants used barrier contraception during weeks 17 to 24, then attempted conception between weeks 25 and 48 [1, 2].

Outcome	Metformin + tirzepatide (n = 28)	Metformin alone (n = 28)	p
Menstrual cycle recovery at week 16	53.6%	21.4%	0.013
Total pregnancy by week 48	57.1%	25.0%	0.014
Natural pregnancy	39.3%	14.3%	0.035
Other pregnancy (ovulation induction, IVF-ET)	17.9%	10.7%	0.705

All pregnancies happened while the women were on metformin alone, after a washout from tirzepatide ^[2]. Broken down by how much weight a woman lost, pregnancy rates were 22.2% in the group losing under 5% of body weight, 50.0% in the 5% to under 10% group, and 50.0% in the 10%-or-more group — a difference that was not statistically significant (p = 0.143) ^[2].

Why would a weight-loss drug affect PCOS at all?

PCOS affects an estimated 11% to 13% of women globally and is a leading cause of ovulatory infertility ^[2]. Insulin resistance, high insulin levels, obesity, and chronic low-grade inflammation interact in its development and progression ^[2]. The relationship between obesity and PCOS runs both directions: obesity is more common in PCOS, contributes to causing it, and worsens its features, while weight loss improves reproductive and metabolic outcomes ^[7].

Mechanistically, obesity-related factors — high leptin, insulin resistance, and high insulin — impair the hypothalamic-pituitary-ovarian axis, lower SHBG, alter androgen levels, and promote anovulation ^[11]. Lifestyle change is the recommended first-line strategy, and metformin, an insulin sensitizer, is commonly used but has limited efficacy ^[2]. Earlier studies found GLP-1 receptor agonists plus metformin superior to metformin alone in PCOS ^[2]. A 2026 review concluded that anti-obesity agents, including tirzepatide, may improve reproductive outcomes primarily indirectly, through weight reduction and metabolic improvement ^[11].

Has tirzepatide been compared head to head with metformin for PCOS?

No. In the single randomized trial, both groups took metformin; the question tested was whether adding tirzepatide helped beyond metformin alone [1, 2]. The PERIODS registry describes tirzepatide’s effects on ovarian dysfunction in PCOS as not yet known ^[5]. A separate systematic review of weight-lowering drugs and natural fertility, first published on 17 June 2026 in Clinical Obesity, screened 2,731 records in a search dated 1 October 2025 and included 7 trials with 575 women, 6 of them randomized, with sample sizes of 40 to 120; 6 trials tested orlistat and 1 tested semaglutide — none tested tirzepatide ^[8]. PERIODS is the placebo-controlled trial designed to answer that question ^[5].

In that Clinical Obesity review, adding semaglutide to metformin raised pregnancy rates to 35% versus 15% with metformin alone, while orlistat versus metformin showed no significant difference in ovulation (RR 0.78) ^[8]. The review also notes that the UK’s NICE recommends liraglutide, semaglutide, and tirzepatide for weight loss ^[8].

How strong is the semaglutide evidence in PCOS?

Stronger than tirzepatide’s in volume, but still thin in quality. A scoping review by La Vignera and Condorelli, published in Biomedicines on 17 August 2026, included 25 studies — only 5 full papers, with the other 23 being abstracts or conference summaries ^[10]. Semaglutide produced mean weight loss of 7.6 to 11.5 kg over 3 to 6 months, with at least 5% weight loss in roughly 80% of patients in responsive cohorts, plus improvements in fasting insulin and HOMA-IR ^[10].

Improvements in menstrual regularity were reported, but those data come largely from conference abstracts and small pilot studies, and the underlying studies are predominantly low-quality observational work ^[10]. On safety, the review flags gastrointestinal events, gallbladder disease, pancreatitis, and the risk of inadvertent pregnancy exposure after ovulation returns — and advises discontinuing before planned conception ^[10].

What do guidelines say about weight-loss drugs in PCOS?

The 2023 International Evidence-based Guideline for the assessment and management of PCOS was published by Teede and colleagues in Human Reproduction in 2023 [6, 7]. The systematic review that informed it, by Goldberg and colleagues in Obesity Reviews in 2024, searched Medline, EMBASE, PsycInfo, and CINAHL through July 2022 with a 10-year limit, and included 11 trials — 545 intervention and 451 control participants across 12 comparisons ^[7].

On descriptive analysis, liraglutide, semaglutide, and orlistat appeared superior to placebo for weight-related outcomes; exenatide versus metformin showed no differences except lower fasting glucose with metformin ^[7]. The review’s conclusion was blunt: published data on anti-obesity agents in PCOS are very limited, and this should be a high research priority ^[7]. Notably, that search closed in July 2022 — years before any tirzepatide PCOS trial, which was published in June 2026 [7, 1]. On diagnosis, the review describes the Rotterdam criteria (2 of 3 features) and notes that the 2018 and 2023 guideline criteria were endorsed by 40 societies internationally ^[7].

Are women with PCOS already being prescribed these drugs?

Yes, and increasingly so — though the best data come from Poland, not the US. Dziewierz and colleagues, publishing in Diabetes, Obesity and Metabolism on 15 June 2026, analyzed electronic health records from the LUX MED private healthcare network covering July 2006 to April 2026 ^[4]. Among 38,263 adult women with ICD-coded PCOS, 4,557 (11.9%) had a recorded GLP-1 receptor agonist or GIP/GLP-1 receptor agonist prescription, while 16,381 (42.8%) received metformin ^[4].

Among the incretin users, 75.5% were also on metformin, and only 11.5% had coded type 2 diabetes ^[4]. Median BMI was 31.2 in incretin users, versus 26.3 in metformin-only women and 22.1 in untreated women ^[4]. Initiation within 365 days of a PCOS diagnosis rose from 0.14% in 2018 to 5.97% in 2024, with an adjusted odds ratio of 1.64 per calendar year ^[4]. The authors describe an expansion beyond glycemic indications toward weight-focused and cardiometabolic management, and call for dispensing, persistence, and safety data ^[4]. Two caveats they note: this is Polish data, and it captures prescriptions recorded, not drugs actually dispensed ^[4].

What side effects were seen?

In the 16-week trial, no serious adverse events or deaths occurred ^[2]. Nausea was the most common event, affecting 23.3% (7 of 30) of the combination arm versus 16.7% (5 of 30) of the metformin arm; diarrhea affected 16.7% versus 13.3%; vomiting occurred in 6.7% of both arms ^[2]. Two women in the metformin arm withdrew due to gastrointestinal intolerance; in the combination arm, one withdrew due to cholecystitis and one due to herpes zoster. Most gastrointestinal events were mild and resolved within 1 month ^[2].

The Zepbound label lists the most common reactions, reported in 5% or more of patients, as nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, and gastroesophageal reflux disease ^[12]. Both labels carry a boxed warning about thyroid C-cell tumors seen in rats, and both are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2; warnings include gallbladder disease, pancreatitis, and severe gastrointestinal reactions [12, 13].

Can I take tirzepatide with birth control pills?

This is a labeled interaction, and it is specific to tirzepatide’s effect on the stomach. Tirzepatide delays gastric emptying, which may reduce the efficacy of oral hormonal contraceptives; the effect is largest after the first dose and diminishes over time [12, 13]. The label advice on both brands is to switch to a non-oral contraceptive method, or add a barrier method, for 4 weeks after initiation and for 4 weeks after each dose escalation [12, 13]. Non-oral hormonal contraceptives should not be affected [12, 13].

The pharmacokinetic basis is measurable. When a combined oral contraceptive (0.035 mg ethinyl estradiol and 0.25 mg norgestimate) was given with a single 5 mg tirzepatide dose, mean Cmax fell by 59% for ethinyl estradiol, 66% for norgestimate, and 55% for norelgestromin, while AUC fell by 20%, 21%, and 23%, and time to peak concentration was delayed by 2.5 to 4.5 hours [12, 13]. As a parallel, the Zepbound label reports that acetaminophen Cmax fell 55% after a first 5 mg dose, with no meaningful effect by week 6 at 15 mg ^[12]. The labels also urge caution with oral drugs that have a narrow therapeutic index, such as warfarin [12, 13]. How this applies to a specific contraceptive is a question for the prescribing clinician.

What about pregnancy and breastfeeding?

The Zepbound label states that weight loss offers no benefit in pregnancy and may cause fetal harm, and advises discontinuing when pregnancy is recognized ^[12]. The Mounjaro label says use in pregnancy only if the potential benefit justifies the potential risk, noting that animal studies showed fetal growth reductions and abnormalities ^[13]. Human pregnancy data are insufficient to evaluate the risk of birth defects or miscarriage on both labels [12, 13], and the Zepbound label points to a pregnancy exposure registry reachable at 1-800-LillyRx ^[12].

Restored ovulation is the hidden risk for women with PCOS. A semaglutide review flags inadvertent pregnancy exposure after ovulatory function returns, and advises stopping before planned conception ^[10]. The Chinese trial required barrier contraception during treatment and for 8 weeks after, with conception attempts only after the washout [1, 2]. PERIODS requires barrier contraception throughout its 72-week treatment period and for 30 days after the last dose ^[5]. On breastfeeding: after a single 5 mg dose in 11 lactating women, tirzepatide was undetectable in 164 of 171 breast milk samples, and the cumulative amount in the remaining samples was under 0.02% of the maternal dose [12, 13].

What is the PERIODS trial, and when will it report?

PERIODS (NCT07326111) is the study designed to give a definitive answer. Sponsored by the University of Bonn, with Charlotte Fries of University Hospital Bonn as responsible party, and registered in the EU as CTIS 2024-515982-32-00, it is a phase 4, multicenter, randomized, double-blind, placebo-controlled trial with quadruple masking, running at 5 sites in Germany. It was listed as recruiting, with a last registry update on 2026-01-08 ^[5].

It plans to enroll 198 women aged 18 to 45, at least 3 years past menarche and premenopausal, with BMI of 27 or higher, PCOS by Rotterdam criteria, oligomenorrhea or secondary amenorrhea (cycles under 21 or over 35 days, or fewer than 8 cycles a year), and hyperandrogenism ^[5]. Exclusions include any GLP-1 or dual agonist use within 6 months, inositol within 6 months, a personal or family history of medullary thyroid carcinoma or MEN 2, a history of pancreatitis, and prior bariatric surgery ^[5]. Participants cannot use hormonal contraceptives for 6 months before or during the trial, and must use barrier contraception during the 72 weeks of treatment and for 30 days after ^[5].

Treatment runs 72 weeks: a 20-week escalation to the maximum tolerated dose, then 52 weeks of maintenance, with placebo pens mimicking doses from 2.5 mg up to 15 mg, and lifestyle advice in both arms ^[5]. The primary endpoint is the mean menstrual bleeding ratio (bleedings per month) over the last 52 weeks; the key secondary is biochemically confirmed ovulations, measured by weekly serum progesterone, within 24 weeks after titration ^[5]. The registry’s dose-response outcome defines an ovulatory event as serum progesterone of at least 3 ng/mL ^[5]. Other endpoints cover cycle normalization, AMH, testosterone, SHBG, DHEA-S, androstenedione, free androgen index, LH, FSH, estradiol, percentage weight change at multiple thresholds, body composition, hirsutism by Ferriman-Gallwey score, acne, and ovarian volume ^[5]. A 52-week off-drug follow-up to week 124 will measure whether cycles stay regular after discontinuation ^[5]. The study started on 2025-12-09, with estimated primary completion in December 2028 and estimated study completion in December 2029 — registry estimates, not promises ^[5]. It is recruiting in Germany only; there is no US enrollment ^[5].

What should I raise with a clinician?

The approved routes to a tirzepatide prescription are the labeled ones: Zepbound’s weight criteria (obesity, or overweight plus a weight-related comorbidity) or Mounjaro’s type 2 diabetes indication; anything else is off-label [12, 13]. The randomized evidence in PCOS is a single trial: 60 women, 16 weeks, a 5 mg dose, open-label, tested as an add-on to metformin rather than against it [1, 2].

Reasonable questions to bring to an appointment include: whether you meet any labeled indication; what a contraception plan looks like around starting the drug and around each dose increase [12, 13]; and how to time a switch if you are planning pregnancy, since the labels and reviews advise stopping before conception and the Zepbound label advises discontinuing if pregnancy is recognized [12, 10]. For a placebo-controlled answer on whether tirzepatide truly improves ovarian function in PCOS, the evidence to watch for is PERIODS, with estimated primary completion in December 2028 ^[5].

Sources

1. Diabetes, Obesity and Metabolism. Short-Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open-Label, Randomised Controlled Trial. 2026.
2. PubMed Central. Short-Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open-Label, Randomised Controlled Trial.
3. Journal of the Endocrine Society. Weight loss outcomes with tirzepatide in women with and without self-reported polycystic ovary syndrome.
4. Diabetes, Obesity and Metabolism. Temporal Trends and Clinical Characteristics of Incretin-Based Therapy Use in Women With Polycystic Ovary Syndrome: A Real-World Cohort Study From a Polish Private Healthcare Network. 2026.
5. ClinicalTrials.gov. A Clinical Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese.
6. Human Reproduction. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome.
7. Obesity Reviews. Anti-obesity pharmacological agents for polycystic ovary syndrome: A systematic review and meta-analysis to inform the 2023 international evidence-based guideline. 2024.
8. Clinical Obesity. Weight-Lowering Drugs and Natural Female Fertility—A Systematic Review and Meta-Analysis. 2026.
9. Maturitas. Tirzepatide and oral progestogens: A hypothesis-generating review of a biologically plausible pharmacokinetic interaction in gynaecologic disease control and menopausal hormone therapy.
10. Biomedicines. Efficacy and Safety of Semaglutide in Patients with Polycystic Ovary Syndrome: A Scoping Review.
11. Medicina. Therapeutic Potential of Anti-Obesity Drugs in Obesity-Associated Female Reproductive Dysfunction: Translating Mechanistic Evidence into Personalized Clinical Strategies.
12. US Food and Drug Administration. ZEPBOUND (tirzepatide) injection, for subcutaneous use: prescribing information. 2026.
13. Eli Lilly and Company. MOUNJARO (tirzepatide) injection, for subcutaneous use: prescribing information.